# Molecular Inflammation Board at the Center for Personalized Medicine

> **NCT07132333** · — · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 3000 (estimated)

## Conditions studied

- Psoriasis (PsO)
- Psoriasis Arthritis
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
- Spondylarthropathies

## Interventions

- **BIOLOGICAL:** Biologic Agent

## Key facts

- **NCT ID:** NCT07132333
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-16
- **Primary completion:** 2032-11
- **Final completion:** 2032-11
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132333, "Molecular Inflammation Board at the Center for Personalized Medicine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07132333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*